Icahn School of Medicine

Mount Sinai AI Center
#Artificial intelligence (AI) #Drug discovery #Icahn School of Medicine #New facility

Mount Sinai launches AI drug discovery centre

The Icahn School of Medicine at Mount Sinai has launched the AI Small Molecule Drug Discovery Center, with the aim of harnessing artificial intelligence (AI) to revolutionise drug development.   The new Center will integrate AI with traditional drug discovery methods to identify and design new small-molecule therapeutics… Read More

#News

Optic nerve
#Icahn School of Medicine #Oculis Holding #Ophthalmology #Phase II trial

“Groundbreaking” results in acute optic neuritis trial

A novel peptidomimetic small molecule candidate has met the primary endpoint in a Phase II trial in patients with acute optic neuritis.  Oculis Holding’s neuroprotective candidate OCS-05 also achieved statistical significance on several key efficacy-based secondary endpoints.  The Phase II Acute OptiC NeUrITis of DemYelinating… Read More

#Editor's Choice #News

Ovarian cancer cells
#Genetics / genomics #Icahn School of Medicine #Immunotherapy #Oncology #Ovarian cancer

Study paves way for improved immunotherapy for ovarian cancer

Researchers have discovered that an eczema-linked protein helps ovarian cancer manipulate its environment to resist immunotherapy, suggesting the potential for a skin drug-based treatment. Scientists at the Icahn School of Medicine at Mount Sinai used spatial genomics technology and preclinical animal models, with tumour specimens from… Read More

#Cancer Research #Editor's Choice #News

Antibodies attack Covid-19
#Antibody #Covid-19 #Icahn School of Medicine #Immunology / Virology & Vaccines #Nanobodies #Virus mutation

Antibody platform overcomes mutational escape in Covid-19

Scientists have developed a unique antibody platform to tackle the challenges of treating rapidly evolving viruses like SARS-CoV-2 due to their ability to mutate and evade therapies. Their findings introduce the Adaptive Multi-Epitope Targeting and Avidity-Enhanced (AMETA) Nanobody Platform. Dr Yi Shi, Associate Professor… Read More

#Editor's Choice #News

Heart monitor
#AAV #Cardiovascular disease #Collaboration #Evox Therapeutics #Gene therapy #Icahn School of Medicine

Research partners advance AAV gene therapy for heart disease

Evox Therapeutics has agreed a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY, US. The collaboration will work on developing exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology aimed at improving… Read More

#News

T cells
#Cancer research #Icahn School of Medicine #Immunotherapy #Melanoma #mRNA #Oncology #Solid tumours

RNA strategy activates dendritic cells and eradicates melanoma tumours

Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. The findings, which suggest that the approach has the potential to be effective against tumours… Read More

#Cancer Research #Editor's Choice #News

Sciatic nerve
#Antidepressants #Boston University #Chronic pain #Icahn School of Medicine #RNA sequencing

Could antidepressant tianeptine treat chronic pain?

Scientists from Boston University have published evidence that the atypical antidepressant tianeptine potentially provides rapid and lasting neuropathic pain relief with a low risk of addiction. The researchers from Boston University Chobanian & Avedisian School of Medicine in collaboration with the Icahn School of Medicine, Columbia… Read More

#Editor's Choice #News

Natural killer cells
#Cancer research #Icahn School of Medicine #Lung cancer #Macrophages #Oncology #Preclinical investigations

Macrophages suppress natural killer cells in lung cancer tumours

Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated in a preclinical study a potential new therapeutic approach to treating the most common form of lung cancer. The strategy involves inhibiting the immune-system molecule TREM2 while enhancing natural killer cells. “Our… Read More

#Cancer Research #News

Female medical researcher
#Genetics #Genetics / genomics #Icahn School of Medicine #Neuroscience #Psychiatry #Schizophrenia

Researchers identify genes that may increase schizophrenia risk

Researchers have identified two previously unknown genes linked to schizophrenia and newly implicated a third gene as carrying risk for both schizophrenia and autism. Led by the Icahn School of Medicine at Mount Sinai, the multi-centre study further demonstrated that the schizophrenia risk conferred by these… Read More

#News